NASDAQ:INCY - Incyte Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $89.60
  • Forecasted Upside: 20.84 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.19 (-1.58%)

This chart shows the closing price for INCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Incyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

Analyst Price Target is $89.60
▲ +20.84% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $89.60, with a high forecast of $109.00 and a low forecast of $67.00. The average price target represents a 20.84% upside from the last price of $74.15.

This chart shows the closing price for INCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Incyte. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 14 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$78.00 ➝ $90.00Medium
1/3/2022GuggenheimLower Price Target$118.00 ➝ $104.00High
12/17/2021JMP SecuritiesReiterated RatingBuy$108.00High
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$75.00Low
11/4/2021JMP SecuritiesLower Price TargetMarket Outperform$124.00 ➝ $108.00High
11/3/2021OppenheimerLower Price TargetOutperform$110.00 ➝ $109.00High
10/15/2021Cantor FitzgeraldLower Price TargetNeutral$104.00 ➝ $79.00Low
10/4/2021Truist FinancialLower Price TargetBuy$120.00 ➝ $95.00Medium
9/24/2021JMP SecuritiesReiterated RatingBuy$124.00Low
9/23/2021Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $80.00Low
9/23/2021Royal Bank of CanadaLower Price TargetSector Perform$91.00 ➝ $86.00Low
8/4/2021SVB LeerinkLower Price TargetUnderperform$70.00 ➝ $67.00Low
7/20/2021BenchmarkUpgradeHold ➝ Buy$89.00Medium
6/25/2021Royal Bank of CanadaLower Price TargetSector Perform$92.00 ➝ $88.00Low
6/15/2021William BlairReiterated RatingOutperformLow
6/15/2021SVB LeerinkReiterated RatingSellLow
5/5/2021Morgan StanleyLower Price TargetEqual Weight$86.00 ➝ $85.00Low
4/5/2021Morgan StanleyLower Price TargetEqual Weight$93.00 ➝ $86.00Low
2/10/2021Morgan StanleyLower Price TargetEqual Weight$97.00 ➝ $93.00Low
2/10/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$89.00 ➝ $70.00Low
1/7/2021Truist FinancialInitiated CoverageBuy$120.00N/A
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
11/9/2020Morgan StanleyLower Price TargetEqual Weight$103.00 ➝ $97.00High
11/6/2020BMO Capital MarketsLower Price TargetMarket Perform$94.00 ➝ $87.00Medium
11/6/2020Royal Bank of CanadaLower Price TargetSector Perform$96.00 ➝ $86.00Medium
10/15/2020Bank of AmericaLower Price TargetBuy$113.00 ➝ $110.00Low
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$100.00 ➝ $103.00Low
8/9/2020CowenReiterated RatingBuyMedium
8/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$90.00 ➝ $94.00Low
8/6/2020Credit Suisse GroupLower Price TargetNeutral$100.00 ➝ $97.00Low
8/6/2020Morgan StanleyBoost Price TargetEqual Weight$95.00 ➝ $100.00Low
8/4/2020MizuhoInitiated CoverageHold$79.00 ➝ $95.00Medium
8/4/2020SVB LeerinkBoost Price TargetMarket Perform$86.00 ➝ $87.00Low
8/3/2020Royal Bank of CanadaBoost Price TargetSector Perform$91.00 ➝ $92.00High
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$99.00Low
7/24/2020William BlairReiterated RatingBuyLow
7/20/2020Credit Suisse GroupBoost Price TargetNeutral$88.00 ➝ $100.00High
7/17/2020OppenheimerReiterated RatingBuy$121.00High
6/17/2020William BlairReiterated RatingBuyLow
6/16/2020BenchmarkInitiated CoverageHoldLow
6/15/2020OppenheimerInitiated CoverageBuy$120.00Medium
6/4/2020ArgusBoost Price TargetBuy$92.00 ➝ $124.00High
5/26/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
5/19/2020Cantor FitzgeraldBoost Price TargetNeutral$83.00 ➝ $100.00Medium
5/12/2020Morgan StanleyBoost Price TargetEqual Weight$94.00 ➝ $95.00High
5/6/2020Credit Suisse GroupReiterated RatingHold$88.00Low
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$74.00 ➝ $90.00Low
5/6/2020NomuraReiterated RatingBuy$116.00Low
5/6/2020OppenheimerBoost Price TargetOutperform$112.00 ➝ $120.00Medium
5/6/2020Royal Bank of CanadaBoost Price TargetIn-Line ➝ Sector Perform$81.00 ➝ $91.00Medium
5/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$89.00 ➝ $99.00Medium
4/29/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$94.00Medium
4/21/2020OppenheimerBoost Price TargetOutperform$90.00 ➝ $112.00Medium
4/20/2020Piper SandlerBoost Price TargetOverweight$95.00 ➝ $110.00Low
4/19/2020MizuhoReiterated RatingHold$79.00Low
4/9/2020William BlairReiterated RatingBuyLow
4/8/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
4/8/2020Nomura SecuritiesReiterated RatingBuy$116.00Medium
4/7/2020OppenheimerBoost Price TargetOutperform$85.00 ➝ $90.00Low
4/6/2020Piper SandlerReiterated RatingBuyHigh
4/1/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00 ➝ $90.00Medium
3/25/2020OppenheimerLower Price Target$99.00 ➝ $85.00High
3/24/2020William BlairInitiated CoverageOutperformHigh
3/18/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
3/13/2020Bank of AmericaUpgradeNeutral ➝ Buy$83.00High
3/11/2020Credit Suisse GroupLower Price TargetNeutral$86.00 ➝ $81.00Medium
2/19/2020Piper SandlerReiterated RatingBuyLow
2/19/2020Nomura SecuritiesBoost Price TargetBuy$111.00 ➝ $116.00Low
2/19/2020CowenReiterated RatingBuyLow
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$89.00Low
2/16/2020Evercore ISIReiterated RatingBuy$92.00Low
2/13/2020MizuhoReiterated RatingHold$79.00High
2/4/2020Bank of AmericaReiterated RatingNeutral$82.00Low
1/30/2020Royal Bank of CanadaReiterated RatingHold$80.00Medium
1/27/2020Evercore ISIReiterated RatingBuy$92.00Low
1/23/2020Cantor FitzgeraldBoost Price TargetNeutral$65.00 ➝ $83.00Low
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
1/14/2020JMP SecuritiesReiterated RatingOutperform$121.00High
1/13/2020CowenReiterated RatingBuyHigh
1/6/2020Royal Bank of CanadaReiterated RatingHold ➝ NeutralHigh
1/6/2020Morgan StanleyLower Price TargetEqual Weight$89.00 ➝ $83.00Low
1/3/2020Royal Bank of CanadaLower Price Target$80.00Medium
1/3/2020The Goldman Sachs GroupLower Price TargetBuy$122.00 ➝ $107.00High
1/3/2020Credit Suisse GroupLower Price TargetNeutral$90.00 ➝ $86.00High
1/3/2020OppenheimerLower Price TargetOutperform$100.00 ➝ $96.00High
1/3/2020BMO Capital MarketsLower Price TargetMarket Perform$85.00 ➝ $74.00High
1/3/2020CitigroupReiterated RatingOutperform$100.00 ➝ $96.00High
1/3/2020JMP SecuritiesLower Price TargetMarket Outperform$110.00 ➝ $99.00High
1/3/2020Cantor FitzgeraldLower Price TargetNeutral$75.00 ➝ $65.00High
1/2/2020MizuhoDowngradeBuy ➝ Neutral$98.00 ➝ $79.00High
1/2/2020Piper Jaffray CompaniesReiterated RatingBuy$95.00High
1/2/2020CowenReiterated RatingBuyHigh
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
12/18/2019MizuhoReiterated RatingBuy$98.00Low
11/27/2019MizuhoReiterated RatingBuy$98.00Low
10/29/2019MizuhoReiterated RatingBuy$95.00Medium
10/2/2019MizuhoInitiated CoverageBuy$95.00Medium
9/30/2019JMP SecuritiesBoost Price TargetBuy ➝ Market Outperform$107.00 ➝ $110.00Medium
9/27/2019CowenReiterated RatingBuyLow
9/27/2019GuggenheimSet Price TargetBuy$101.00Low
9/12/2019BMO Capital MarketsInitiated CoverageMarket Perform$85.00High
9/5/2019Morgan StanleyBoost Price TargetEqual ➝ Equal Weight$82.00 ➝ $87.00High
9/5/2019OppenheimerUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Medium
9/5/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$107.00Medium
8/4/2019CowenReiterated RatingBuyLow
7/31/2019SVB LeerinkSet Price TargetHold$90.00Medium
7/31/2019Nomura SecuritiesBoost Price TargetBuy$100.00 ➝ $111.00Low
7/31/2019JPMorgan Chase & Co.Reiterated RatingBuy$91.00Low
7/31/2019Morgan StanleyBoost Price TargetEqual Weight$81.00 ➝ $82.00Low
6/17/2019Piper Jaffray CompaniesReiterated RatingBuyLow
5/27/2019CowenReiterated RatingBuyLow
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$75.00Medium
5/15/2019Piper Jaffray CompaniesBoost Price TargetOverweight$85.00 ➝ $95.00Low
5/15/2019JPMorgan Chase & Co.Reiterated RatingBuy$90.00Low
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$90.00 ➝ $82.00High
4/30/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
4/22/2019CowenReiterated RatingBuyLow
4/14/2019BarclaysReiterated RatingBuy$90.00High
4/10/2019Stifel NicolausInitiated CoverageHold$82.00 ➝ $82.00Medium
4/7/2019OppenheimerSet Price TargetHold$85.00Low
4/3/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$89.00High
2/25/2019ArgusBoost Price TargetBuy ➝ Buy$83.00 ➝ $98.00Low
2/15/2019Raymond JamesSet Price TargetBuy$100.00Low
2/15/2019Royal Bank of CanadaBoost Price TargetOutperform$89.00High
2/11/2019JMP SecuritiesReiterated RatingHoldLow
2/5/2019SunTrust BanksBoost Price TargetBuy$90.00Low
1/24/2019William BlairUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Low
1/23/2019GabelliUpgradeHold ➝ Buy$105.00Medium
1/16/2019UBS GroupDowngradeBuy ➝ Neutral$75.00 ➝ $82.00Medium
1/15/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
1/3/2019GuggenheimUpgradeNeutral ➝ BuyHigh
12/9/2018CowenReiterated RatingBuyLow
12/3/2018CowenReiterated RatingBuyHigh
10/30/2018JPMorgan Chase & Co.Set Price TargetBuy$88.00High
10/30/2018CowenReiterated RatingBuyHigh
10/25/2018Raymond JamesReiterated RatingBuy$85.00Low
10/21/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Hold$73.00 ➝ $74.00Low
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$73.00Low
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$78.00Low
9/17/2018GuggenheimInitiated CoverageNeutralLow
9/15/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
9/13/2018OppenheimerSet Price TargetHold$70.00Low
9/4/2018CowenReiterated RatingBuyHigh
8/30/2018ArgusSet Price TargetBuy$83.00Low
8/15/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$74.00Low
8/1/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
8/1/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
7/31/2018OppenheimerSet Price TargetHold$70.00Medium
7/31/2018CowenReiterated RatingBuyHigh
7/27/2018Raymond JamesReiterated RatingBuyMedium
7/17/2018OppenheimerSet Price TargetMarket Perform ➝ Hold$65.00 ➝ $70.00Low
7/13/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
6/26/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$76.00 ➝ $74.00High
6/24/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
6/11/2018Evercore ISIUpgradeIn-Line ➝ Outperform$60.23 ➝ $140.11Medium
6/1/2018OppenheimerSet Price TargetHold$65.00Low
5/30/2018Piper Jaffray CompaniesInitiated CoverageBuy$85.00Low
5/2/2018CowenReiterated RatingBuyLow
5/1/2018OppenheimerSet Price TargetHold$65.00Low
5/1/2018Raymond JamesReiterated RatingBuyLow
4/24/2018Raymond JamesReiterated RatingBuyHigh
4/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$96.00 ➝ $88.00High
4/23/2018OppenheimerSet Price TargetHold$65.00High
4/17/2018Credit Suisse GroupSet Price TargetBuy$78.00Low
4/12/2018UBS GroupUpgradeNeutral ➝ Buy$76.00Low
4/9/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$149.00 ➝ $96.00Low
4/9/2018Credit Suisse GroupLower Price TargetOutperform$146.00 ➝ $76.00High
4/9/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$142.00 ➝ $76.00High
4/9/2018GabelliDowngradeBuy ➝ HoldMedium
4/9/2018Nomura SecuritiesLower Price TargetBuy$102.00Low
4/9/2018OppenheimerSet Price TargetHold$110.00 ➝ $65.00Low
4/6/2018Credit Suisse GroupSet Price TargetOutperform ➝ Outperform$145.00 ➝ $78.00Medium
4/6/2018SunTrust BanksReiterated RatingBuy$80.00Low
4/6/2018Raymond JamesSet Price TargetBuy$85.00High
4/6/2018GuggenheimReiterated RatingBuy ➝ NeutralHigh
4/6/2018William BlairReiterated RatingOutperform ➝ Market PerformHigh
4/5/2018BarclaysLower Price TargetOverweight ➝ Overweight$165.00 ➝ $135.00Low
2/28/2018Raymond JamesSet Price TargetBuy$159.00Medium
2/20/2018OppenheimerSet Price TargetHold$110.00Low
2/15/2018Raymond JamesReiterated RatingBuyLow
2/14/2018Credit Suisse GroupSet Price TargetBuy$145.00High
2/1/2018Nomura SecuritiesReiterated RatingBuyHigh
1/22/2018OppenheimerReiterated RatingHold$120.00 ➝ $110.00Low
1/3/2018BMO Capital MarketsReiterated RatingBuy$172.00Low
1/2/2018CitigroupReiterated RatingMarket Perform$135.00 ➝ $120.00High
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$136.00High
1/2/2018OppenheimerSet Price TargetHold$120.00High
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$106.00Medium
12/12/2017Raymond JamesReiterated RatingBuyMedium
12/5/2017CowenReiterated RatingBuyLow
11/21/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$136.00 ➝ $120.00N/A
10/31/2017OppenheimerSet Price TargetHold$135.00N/A
10/31/2017BMO Capital MarketsBoost Price TargetOutperform$162.00 ➝ $166.00N/A
10/31/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/26/2017BMO Capital MarketsLower Price TargetOutperform$163.00 ➝ $162.00N/A
10/25/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
10/6/2017The Goldman Sachs GroupInitiated CoverageBuy$160.00N/A
10/6/2017Jefferies Financial GroupReiterated RatingBuyN/A
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$136.00Low
9/13/2017ArgusReiterated RatingBuy$150.00Low
9/11/2017BMO Capital MarketsReiterated RatingOutperform$172.00 ➝ $163.00Low
9/11/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$159.00High
9/10/2017OppenheimerReiterated RatingHold$135.00Low
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuy$149.00High
8/31/2017OppenheimerReiterated RatingHold$135.00High
8/28/2017BMO Capital MarketsReiterated RatingOutperform$172.00Medium
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$135.00Medium
8/2/2017BarclaysReiterated RatingOverweight$180.00 ➝ $165.00Low
8/1/2017JPMorgan Chase & Co.Set Price TargetBuy$149.00Low
7/27/2017Jefferies Financial GroupReiterated RatingBuy$148.00Medium
7/21/2017BMO Capital MarketsReiterated RatingBuy$172.00High
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00Low
7/4/2017Jefferies Financial GroupReiterated RatingBuy$165.00Medium
7/4/2017BarclaysBoost Price TargetOverweight$135.00 ➝ $185.00Medium
7/3/2017CowenReiterated RatingOutperform$130.00Medium
6/28/2017GabelliReiterated RatingBuy$174.00Medium
6/20/2017Jefferies Financial GroupReiterated RatingBuy$148.00Medium
6/10/2017Credit Suisse GroupReiterated RatingBuyMedium
6/6/2017OppenheimerSet Price TargetHold$135.00Low
6/6/2017BarclaysReiterated RatingOverweight$180.00Medium
6/5/2017BMO Capital MarketsReiterated RatingOutperform$155.00 ➝ $166.00Medium
6/5/2017CowenReiterated RatingBuyMedium
5/31/2017CIBCBoost Price TargetOutperform$125.00 ➝ $135.00Low
5/31/2017OppenheimerReiterated RatingOutperform$125.00 ➝ $135.00Medium
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00Medium
5/18/2017OppenheimerSet Price TargetHold$125.00High
5/18/2017JPMorgan Chase & Co.Set Price TargetBuy$149.00Medium
5/18/2017Jefferies Financial GroupReiterated RatingBuy$148.00Low
5/15/2017CowenReiterated RatingBuyN/A
5/15/2017BMO Capital MarketsBoost Price TargetOutperform$144.00 ➝ $146.00N/A
5/12/2017CIBCReiterated RatingMarket Perform ➝ Market Perform$125.00Low
5/12/2017OppenheimerInitiated CoverageMarket Perform$125.00Medium
5/9/2017Credit Suisse GroupSet Price TargetOutperform$167.00 ➝ $152.00Low
5/5/2017BMO Capital MarketsBoost Price TargetOutperform$144.00 ➝ $146.00Low
5/5/2017CowenReiterated RatingBuyHigh
4/19/2017SunTrust BanksLower Price TargetBuy$160.00 ➝ $145.00Low
4/19/2017BMO Capital MarketsLower Price TargetOutperform$170.00 ➝ $144.00High
4/19/2017Credit Suisse GroupSet Price TargetBuy$167.00Low
4/19/2017BarclaysLower Price TargetOverweight$185.00 ➝ $180.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$174.00Low
4/18/2017Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $150.00Low
4/18/2017The Goldman Sachs GroupLower Price TargetBuy$149.00 ➝ $136.00Low
4/17/2017Raymond JamesReiterated RatingHoldHigh
4/17/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$165.00 ➝ $148.00Low
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Neutral$124.00Medium
4/10/2017GabelliInitiated CoverageBuy ➝ Buy$185.00Medium
4/8/2017BarclaysSet Price TargetBuy$135.00Medium
4/7/2017BarclaysBoost Price TargetOverweight$135.00 ➝ $185.00Low
4/6/2017Raymond JamesDowngradeOutperform ➝ HoldMedium
4/6/2017Jefferies Financial GroupReiterated RatingBuy$165.00Medium
4/5/2017Raymond JamesReiterated RatingOutperform ➝ Market Perform$135.00Medium
4/5/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
4/4/2017Royal Bank of CanadaBoost Price TargetOutperform$138.00 ➝ $157.00Low
4/3/2017BMO Capital MarketsBoost Price TargetOutperform$140.00 ➝ $170.00Medium
4/3/2017CowenReiterated RatingOutperformHigh
3/31/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Buy$138.00High
3/21/2017William BlairInitiated CoverageOutperformLow
3/9/2017UBS GroupInitiated CoverageNeutral ➝ Neutral$140.00N/A
3/8/2017CowenReiterated RatingOutperformMedium
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$148.00N/A
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
2/21/2017Jefferies Financial GroupReiterated RatingBuy$140.00N/A
2/16/2017BMO Capital MarketsReiterated RatingOutperform$135.00 ➝ $149.00N/A
2/16/2017JPMorgan Chase & Co.Reiterated RatingBuy$136.00N/A
2/15/2017Jefferies Financial GroupBoost Price TargetBuy$136.00 ➝ $140.00N/A
2/15/2017Royal Bank of CanadaBoost Price TargetOutperform$123.00 ➝ $138.00N/A
2/14/2017Royal Bank of CanadaReiterated RatingOutperform$123.00 ➝ $138.00N/A
1/27/2017The Goldman Sachs GroupBoost Price TargetBuy$116.00 ➝ $149.00N/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 14 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
  • 7 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 7 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 41 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 3 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 3 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 4 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Incyte logo
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More

Today's Range

Now: $74.15
Low: $72.67
High: $75.04

50 Day Range

MA: $70.73
Low: $63.34
High: $75.34

52 Week Range

Now: $74.15
Low: $61.91
High: $101.33


1,715,632 shs

Average Volume

1,906,851 shs

Market Capitalization

$16.38 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

The following equities research analysts have issued research reports on Incyte in the last twelve months: Benchmark Co., BMO Capital Markets, Cantor Fitzgerald, Guggenheim, JMP Securities, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, TheStreet, Truist Financial Co., and William Blair.
View the latest analyst ratings for INCY.

What is the current price target for Incyte?

10 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $89.60, suggesting a possible upside of 20.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting INCY will reach $109.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $67.00 for Incyte in the next year.
View the latest price targets for INCY.

What is the current consensus analyst rating for Incyte?

Incyte currently has 1 sell rating, 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INCY will outperform the market and that investors should add to their positions of Incyte.
View the latest ratings for INCY.

How do I contact Incyte's investor relations team?

Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is (302) 498-6700 and its investor relations email address is [email protected] The official website for Incyte is